Protein scaffold engineering for immune checkpoint targeting, tumor microenvironment modulation, and Cancer...

Area of Science:

• Biotechnology
• Immunology
• Oncology

Background:

• Traditional cancer immunotherapy faces challenges including high production costs, limited tumor penetration, immune-related toxicity, and therapeutic resistance.
• Monoclonal antibodies (mAbs) are effective but have limitations that novel protein scaffolds aim to address.

Purpose of the Study:

• To explore the development and therapeutic potential of protein scaffolds as novel non-antibody-binding platforms in cancer immunotherapy.
• To highlight the advantages of protein scaffolds over traditional methods and discuss their mechanisms, engineering, and future directions.

Main Methods:

• Utilizing various protein scaffold types (Affibodies, DARPins, Anticalins, Monobodies, Knottins, Avimers) with modular designs.
• Employing engineering approaches like display technologies (phage, yeast, ribosome), directed evolution, and computational design.
• Implementing strategies for half-life extension such as PEGylation, albumin fusion, and FC linkage.

Main Results:

• Protein scaffolds demonstrate structural stability, small size, high solubility, rapid clearance, and effective recombinant production.
• Scaffolds enable targeted engagement of tumor antigens, immune checkpoints (CTLA-4, PD-1/PD-L1, LAG-3), and the tumor microenvironment (TME).
• Mechanisms include oncogenic pathway suppression, T-cell restoration, cytokine regulation, and high-resolution tumor imaging (e.g., KRAS-binding DARPins, HER2-targeted affibody ABY-025).

Conclusions:

• Protein scaffolds represent a rapidly emerging therapeutic class with immense potential to revolutionize targeted cancer immunotherapy and personalized diagnostics.
• Future developments may involve AI-assisted modifications, multi-functional immunomodulatory structures, and integration with personalized neoantigen treatments.
• Despite challenges like renal clearance and potential immunogenicity, scaffolds offer significant advantages for next-generation cancer therapies.